PACIRA BIOSCIENCES, INC. Payments of Debt Issuance Costs
PACIRA BIOSCIENCES, INC. (PCRX) reported Payments of Debt Issuance Costs of $1.18 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2023-02-28
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for the quarter ending 2018-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for the quarter ending 2018-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for the quarter ending 2018-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for fiscal 2022 was $1.18M, a 74.15% decline from fiscal 2021.
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for fiscal 2021 was $4.55M, a 63.59% decline from fiscal 2020.
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for fiscal 2020 was $12.49M.
- PACIRA BIOSCIENCES, INC. payments of debt issuance costs for fiscal 2019 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.18M 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $4.55M 10-K · filed 2023-02-28 | |||
| 2020-12-31 | $12.49M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | $0.00 derived: sum of 3 quarters · filed 2020-02-21 | $0.00 derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-03 | $0.00 derived: sum of 2 quarters · filed 2020-02-21 | $0.00 derived: sum of 3 quarters · filed 2020-02-21 | $0.00 derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $0.00 derived: sum of 2 quarters · filed 2020-02-21 | $0.00 derived: sum of 3 quarters · filed 2020-02-21 | $11.00M 10-K · filed 2020-02-21 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $11.00M 10-Q · filed 2018-11-01 | $11.00M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $11.00M 10-Q · filed 2018-08-02 | $11.00M derived: sum of 3 quarters · filed 2019-02-28 | $11.00M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $11.00M 10-Q · filed 2018-05-03 | $11.00M derived: sum of 2 quarters · filed 2019-02-28 | $11.00M derived: sum of 3 quarters · filed 2019-02-28 | $11.00M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $0.00 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |